Bret Wehrli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bret Wehrli has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Stephanie Danielle MacNeil
Department of Otolaryngology—Head and Neck Surgery, Western University, London, ON, Canada
4 shared publications Andrew Warner
Division of Radiation Oncology, Department of Oncology, Western University, London, ON, Canada
3 shared publications- Anthony Charles Nichols
Department of Otolaryngology—Head and Neck Surgery, Western University, London, ON, Canada
3 shared publications - David Anthony Palma
Department of Radiation Oncology, London Health Sciences Centre, Western University, London, Canada
3 shared publications - Eric Winquist
Division of Medical Oncology, Department of Oncology, Western University, London, ON, Canada
3 shared publications John Yoo
Department of Otolaryngology—Head and Neck Surgery, Western University, London, ON, Canada
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study
Purpose: PIK3CA -activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negative head and neck squamous cell carcinomas (HNSCCs). PI3K pathway inhibition is postulated as a potential therapeutic strategy, and preclinical studies have demonstrated that the PI3Kα selective inhibitor alpelisib has broad tumoristatic activity across HNSCC genotypes. Methods: In this trial, patients with oral cavity HNSCC received either 400 mg or 200 mg of alpelisib once daily for up to 14 days preoperatively. The primary end point was the change in phosphorylated S6 (Ser235/236) expression in paired pre- and post-treatment tumor samples as assessed by immunohistochemistry. Secondary end points included changes in tumor size, pathologic response, phospho-AKT, Ki-67, and transcriptome differences between baseline and post-treatment tumor samples, as well as associations between baseline genomic variants and tumor response. Results: Of the 15 patients enrolled, 14 completed the treatment. The first five patients received a dose of 400 mg once daily; however, three of five patients experienced grade 3 hypertension, fatigue, and oral mucositis; thus, the protocol was amended with a lower dose of 200 mg for the subsequent 10 patients. Pre- and post-treatment tumor samples were available for 13 patients. Of the 13 patients analyzed, eight patients had decreased levels of phosphorylated S6 serine 235/236, whereas three patients had no change and two patients had increased levels. Two clinical partial responses as per RECIST 1.1 were observed (13.3%); however, there were no pathological responses. Molecular profiling revealed seven patients had PIK3CA amplification, and no patients had PIK3CA point mutations. NanoString analysis demonstrated that alpelisib induced tumor transcriptome changes, including decreases in SPP1 transcript abundance. Conclusion: Preoperative alpelisib achieved a 13.3% response rate, reduced phospho-S6 Ser235/236 levels in eight of 13 patients, and induced tumor transcriptomic changes.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Open AccessNeoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study
Purpose: PIK3CA -activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negative head and neck squamous cell carcinomas (HNSCCs). PI3K pathway inhibition is postulated as a potential therapeutic strategy, and preclinical studies have demonstrated that the PI3Kα selective inhibitor alpelisib has broad tumoristatic activity across HNSCC genotypes. Methods: In this trial, patients with oral cavity HNSCC received either 400 mg or 200 mg of alpelisib once daily for up to 14 days preoperatively. The primary end point was the change in phosphorylated S6 (Ser235/236) expression in paired pre- and post-treatment tumor samples as assessed by immunohistochemistry. Secondary end points included changes in tumor size, pathologic response, phospho-AKT, Ki-67, and transcriptome differences between baseline and post-treatment tumor samples, as well as associations between baseline genomic variants and tumor response. Results: Of the 15 patients enrolled, 14 completed the treatment. The first five patients received a dose of 400 mg once daily; however, three of five patients experienced grade 3 hypertension, fatigue, and oral mucositis; thus, the protocol was amended with a lower dose of 200 mg for the subsequent 10 patients. Pre- and post-treatment tumor samples were available for 13 patients. Of the 13 patients analyzed, eight patients had decreased levels of phosphorylated S6 serine 235/236, whereas three patients had no change and two patients had increased levels. Two clinical partial responses as per RECIST 1.1 were observed (13.3%); however, there were no pathological responses. Molecular profiling revealed seven patients had PIK3CA amplification, and no patients had PIK3CA point mutations. NanoString analysis demonstrated that alpelisib induced tumor transcriptome changes, including decreases in SPP1 transcript abundance. Conclusion: Preoperative alpelisib achieved a 13.3% response rate, reduced phospho-S6 Ser235/236 levels in eight of 13 patients, and induced tumor transcriptomic changes.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (34) , 4023-4028
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial
Radiotherapy (RT) and transoral robotic surgery (TORS) are both curative-intent treatment options for oropharyngeal squamous cell carcinoma (OPSCC). Herein, we report the final outcomes of the ORATOR trial comparing these modalities, 5 years after enrollment completion. We randomly assigned 68 patients with T1-2N0-2 OPSCC to RT (with chemotherapy if node-positive) versus TORS plus neck dissection (± adjuvant RT/chemoradiation). The primary end point was swallowing quality of life (QOL) assessed with the MD Anderson Dysphagia Inventory (MDADI). Secondary end points included overall and progression-free survival (OS, PFS), adverse events (AEs), and other QOL metrics. The primary end point has been previously reported (Nichols 2019). In this report, the median follow-up was 5.1 years (IQR, 5.0-5.3 years). MDADI total scores converged by 5 years and were not significantly different across the follow-up period ( P = .11). EORTC QLQ-C30 and H&N35 scores demonstrated differing profiles, including worse dry mouth in the RT arm ( P = .032) and worse pain in the TORS arm ( P = .002). Grade 2-5 AE rates did not differ between arms (91% [n = 31] v 97% [n = 33] respectively, P = .61), with more neutropenia and hearing loss in the RT arm, and more dysphagia and other pain in the TORS arm based on grades 2-5 (all P < .05). There were no differences in OS or PFS. In conclusion, toxicity and QOL profiles differ in some domains between RT and TORS, but oncologic outcomes were excellent in both arms. Choice of treatment should remain a shared decision between the patient and their providers.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (34) , 4023-4028
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial
Radiotherapy (RT) and transoral robotic surgery (TORS) are both curative-intent treatment options for oropharyngeal squamous cell carcinoma (OPSCC). Herein, we report the final outcomes of the ORATOR trial comparing these modalities, 5 years after enrollment completion. We randomly assigned 68 patients with T1-2N0-2 OPSCC to RT (with chemotherapy if node-positive) versus TORS plus neck dissection (± adjuvant RT/chemoradiation). The primary end point was swallowing quality of life (QOL) assessed with the MD Anderson Dysphagia Inventory (MDADI). Secondary end points included overall and progression-free survival (OS, PFS), adverse events (AEs), and other QOL metrics. The primary end point has been previously reported (Nichols 2019). In this report, the median follow-up was 5.1 years (IQR, 5.0-5.3 years). MDADI total scores converged by 5 years and were not significantly different across the follow-up period ( P = .11). EORTC QLQ-C30 and H&N35 scores demonstrated differing profiles, including worse dry mouth in the RT arm ( P = .032) and worse pain in the TORS arm ( P = .002). Grade 2-5 AE rates did not differ between arms (91% [n = 31] v 97% [n = 33] respectively, P = .61), with more neutropenia and hearing loss in the RT arm, and more dysphagia and other pain in the TORS arm based on grades 2-5 (all P < .05). There were no differences in OS or PFS. In conclusion, toxicity and QOL profiles differ in some domains between RT and TORS, but oncologic outcomes were excellent in both arms. Choice of treatment should remain a shared decision between the patient and their providers.
- Open Access
- 4 July 2024
- Published by Taylor & Francis in Case Reports in Plastic Surgery and Hand Surgery
- Vol. 11 (1) , 2374550
Idiopathic avascular necrosis of the scaphoid (Preiser’s disease): a case report and review of the literature
Idiopathic avascular necrosis of the scaphoid bone, Preiser’s disease, was originally described as a deteriorative pathology whereby the osseous structure necroses due to loss of blood supply. It may present with multifactorial etiology, which is still largely not well understood. We describe a case of Preiser’s disease in a 70-year-old female, with worsening pain and loss of range of motion in her right wrist over a two-year period. Past medical history was significant for Sjogren’s disease, fibromyalgia, and dystonia. Pain began several months following traumatic right dorsal wrist injury. Diagnosis of traumatic scaphoid fracture was originally suspected. Conservative treatment was unsuccessful. Radiographs did not demonstrate evidence of primary fracture. CT scan and MRI demonstrated osteonecrosis of the proximal pole of the scaphoid, but no evidence of fracture, either residual or healing, was found. Proximal row carpectomy was performed for avascular necrosis of the scaphoid. Histology confirmed diagnosis and verified absence of fracture. Postoperatively, the patient’s pain and range of motion improved. This report combines histological findings of Preiser’s disease with radiographic images which may ameliorate understanding of the clinical pathophysiology. We describe an unusual manifestation of Preiser’s disease whereby a single traumatic event, in the absence of fracture, led to idiopathic scaphoid avascular necrosis, which may have been associated with Sjogren’s syndrome and fibromyalgia. These conditions may have negatively impacted microvasculature and decreased bone mineral density, inversely correlated with the production of fatty marrow, facilitating the onset of osteonecrosis in the scaphoid.
- 4 July 2024
- Published by Taylor & Francis in Case Reports in Plastic Surgery and Hand Surgery
- Vol. 11 (1) , 2374550
Open AccessIdiopathic avascular necrosis of the scaphoid (Preiser’s disease): a case report and review of the literature
Idiopathic avascular necrosis of the scaphoid bone, Preiser’s disease, was originally described as a deteriorative pathology whereby the osseous structure necroses due to loss of blood supply. It may present with multifactorial etiology, which is still largely not well understood. We describe a case of Preiser’s disease in a 70-year-old female, with worsening pain and loss of range of motion in her right wrist over a two-year period. Past medical history was significant for Sjogren’s disease, fibromyalgia, and dystonia. Pain began several months following traumatic right dorsal wrist injury. Diagnosis of traumatic scaphoid fracture was originally suspected. Conservative treatment was unsuccessful. Radiographs did not demonstrate evidence of primary fracture. CT scan and MRI demonstrated osteonecrosis of the proximal pole of the scaphoid, but no evidence of fracture, either residual or healing, was found. Proximal row carpectomy was performed for avascular necrosis of the scaphoid. Histology confirmed diagnosis and verified absence of fracture. Postoperatively, the patient’s pain and range of motion improved. This report combines histological findings of Preiser’s disease with radiographic images which may ameliorate understanding of the clinical pathophysiology. We describe an unusual manifestation of Preiser’s disease whereby a single traumatic event, in the absence of fracture, led to idiopathic scaphoid avascular necrosis, which may have been associated with Sjogren’s syndrome and fibromyalgia. These conditions may have negatively impacted microvasculature and decreased bone mineral density, inversely correlated with the production of fatty marrow, facilitating the onset of osteonecrosis in the scaphoid.
- Top Cited Papers
- 10 March 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (8) , 866-875
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial
PURPOSE: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen rapidly, because of an epidemic of human papillomavirus infection. The optimal management of early-stage OPSCC with surgery or radiation continues to be a clinical controversy. Long-term randomized data comparing these paradigms are lacking. METHODS: We randomly assigned patients with T1-T2, N0-2 (≤ 4 cm) OPSCC to radiotherapy (RT) (with chemotherapy if N1-2) versus transoral robotic surgery plus neck dissection (TORS + ND) (with or without adjuvant therapy). The primary end point was swallowing quality of life (QOL) at 1-year using the MD Anderson Dysphagia Inventory. Secondary end points included adverse events, other QOL outcomes, overall survival, and progression-free survival. All analyses were intention-to-treat. Herein, we present long-term outcomes from the trial. RESULTS: Sixty-eight patients were randomly assigned (n = 34 per arm) between August 10, 2012, and June 9, 2017. Median follow-up was 45 months. Longitudinal MD Anderson Dysphagia Inventory analyses demonstrated statistical superiority of RT arm over time ( P = .049), although the differences beyond 1 year were of smaller magnitude than at the 1-year timepoint (year 2: 86.0 ± 13.5 in the RT arm v 84.8 ± 12.5 in the TORS + ND arm, P = .74; year 3: 88.9 ± 11.3 v 83.3 ± 13.9, P = .12). These differences did not meet the threshold to qualify as a clinically meaningful change at any timepoint. Certain differences in QOL concerns including more pain and dental concerns in the TORS + ND arm seen at 1 year resolved at 2 and 3 years; however, TORS patients started to use more nutritional supplements at 3 years ( P = .015). Dry mouth scores were higher in RT patients over time ( P = .041). CONCLUSION: On longitudinal analysis, the swallowing QOL difference between primary RT and TORS + ND approaches persists but decreases over time. Patients with OPSCC should be informed about the pros and cons of both treatment options (ClinicalTrials.gov identifier: NCT01590355 ).
- 10 March 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (8) , 866-875
Top Cited PapersRandomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial
PURPOSE: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen rapidly, because of an epidemic of human papillomavirus infection. The optimal management of early-stage OPSCC with surgery or radiation continues to be a clinical controversy. Long-term randomized data comparing these paradigms are lacking. METHODS: We randomly assigned patients with T1-T2, N0-2 (≤ 4 cm) OPSCC to radiotherapy (RT) (with chemotherapy if N1-2) versus transoral robotic surgery plus neck dissection (TORS + ND) (with or without adjuvant therapy). The primary end point was swallowing quality of life (QOL) at 1-year using the MD Anderson Dysphagia Inventory. Secondary end points included adverse events, other QOL outcomes, overall survival, and progression-free survival. All analyses were intention-to-treat. Herein, we present long-term outcomes from the trial. RESULTS: Sixty-eight patients were randomly assigned (n = 34 per arm) between August 10, 2012, and June 9, 2017. Median follow-up was 45 months. Longitudinal MD Anderson Dysphagia Inventory analyses demonstrated statistical superiority of RT arm over time ( P = .049), although the differences beyond 1 year were of smaller magnitude than at the 1-year timepoint (year 2: 86.0 ± 13.5 in the RT arm v 84.8 ± 12.5 in the TORS + ND arm, P = .74; year 3: 88.9 ± 11.3 v 83.3 ± 13.9, P = .12). These differences did not meet the threshold to qualify as a clinically meaningful change at any timepoint. Certain differences in QOL concerns including more pain and dental concerns in the TORS + ND arm seen at 1 year resolved at 2 and 3 years; however, TORS patients started to use more nutritional supplements at 3 years ( P = .015). Dry mouth scores were higher in RT patients over time ( P = .041). CONCLUSION: On longitudinal analysis, the swallowing QOL difference between primary RT and TORS + ND approaches persists but decreases over time. Patients with OPSCC should be informed about the pros and cons of both treatment options (ClinicalTrials.gov identifier: NCT01590355 ).
- Open Access
- 1 October 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (43) , e6927
An atypical lipomatous tumor mimicking a giant fibrovascular polyp of the hypopharynx
Giant fibrovascular polyps (GFVPs) found in the hypopharynx are exceedingly rare. These are benign tumors which are identified by CT or MRI and usually treated based on symptoms. Even more rarely, pathology may identify one of these masses as an atypical lipomatous tumor (ALT). This paper will present a case of an ALT of the hypopharynx that was originally classified as a GFVP, highlighting the difficulty in distinguishing between them and the importance of making the correct diagnosis. An 84-year-old man presented to the emergency department with a 6-month history of a pedunculated hypopharyngeal growth, dysphagia, and intermittent dyspnea. The mass was characterized as a GFVP by barium swallow and MRI. The hypopharyngeal mass was resected for obstructive symptoms and to confirm the diagnosis. Final pathology found the mass to be more consistent with an atypical lipomatous tumor (ALT). The patient's dysphagia and dyspnea resolved. He was free of recurrence at 22 months postoperative. Both GFVPs and ALTs are very rarely found in the hypopharynx but can be easily misclassified as one another. Imaging is useful to initially characterize the mass, but to definitively differentiate between them, pathological analysis is necessary. Although they are rare, it is important to consider both possibilities on the differential for hypopharyngeal masses. Further, accurate analysis is essential to distinguish between them because their definitive management and follow-up is different.
- 1 October 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (43) , e6927
Open AccessAn atypical lipomatous tumor mimicking a giant fibrovascular polyp of the hypopharynx
Giant fibrovascular polyps (GFVPs) found in the hypopharynx are exceedingly rare. These are benign tumors which are identified by CT or MRI and usually treated based on symptoms. Even more rarely, pathology may identify one of these masses as an atypical lipomatous tumor (ALT). This paper will present a case of an ALT of the hypopharynx that was originally classified as a GFVP, highlighting the difficulty in distinguishing between them and the importance of making the correct diagnosis. An 84-year-old man presented to the emergency department with a 6-month history of a pedunculated hypopharyngeal growth, dysphagia, and intermittent dyspnea. The mass was characterized as a GFVP by barium swallow and MRI. The hypopharyngeal mass was resected for obstructive symptoms and to confirm the diagnosis. Final pathology found the mass to be more consistent with an atypical lipomatous tumor (ALT). The patient's dysphagia and dyspnea resolved. He was free of recurrence at 22 months postoperative. Both GFVPs and ALTs are very rarely found in the hypopharynx but can be easily misclassified as one another. Imaging is useful to initially characterize the mass, but to definitively differentiate between them, pathological analysis is necessary. Although they are rare, it is important to consider both possibilities on the differential for hypopharyngeal masses. Further, accurate analysis is essential to distinguish between them because their definitive management and follow-up is different.
- Open Access
- 1 September 2012
- Published by SAGE Publications in Archives of Facial Plastic Surgery
- Vol. 14 (5) , 369-371
The Hyoplatysmal Ligament
Research from JAMA Facial Plastic Surgery — The Hyoplatysmal Ligament — Characterization and Biomechanical Properties
- 1 September 2012
- Published by SAGE Publications in Archives of Facial Plastic Surgery
- Vol. 14 (5) , 369-371
Open AccessThe Hyoplatysmal Ligament
Research from JAMA Facial Plastic Surgery — The Hyoplatysmal Ligament — Characterization and Biomechanical Properties